Leora Horn MD MSc, MHPE

Oncology•Nashville, TN

Assistant Professor, Medicine, Vanderbilt University School of Medicine

Join to View Full Profile

3601 TvcNashville, TN 37232
Phone+1 615-322-3000

Education & Training

University of Toronto Faculty of MedicineClass of 2002

Certifications & Licensure

TN State Medical License 2009 - 2025

Clinical Trials

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
Completed
Phase 2
NCI 8873: Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCL Start of enrollment: 2011 Jun 01
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 1, Phase 2
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer Start of enrollment: 2012 Oct 01
Terminated
Early Phase 1
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
Terminated
Phase 1
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
COMPLETED
PHASE3
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib Start of enrollment: 2014 Jun 01
Withdrawn
Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer Start of enrollment: 2017 Jul 20
Terminated
Phase 1
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Start of enrollment: 2018 Jul 10
COMPLETED
PHASE1, PHASE2
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Apr 02
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials.
David E Gerber, Claire R Wynters, Tanushree Prasad, Ronny K Schnel, Song Zhang
Clinical Cancer Research. 2025-03-17
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
Mitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, Leora Horn, D Ross Camidge
Clinical Cancer Research. 2025-02-17
Afatinib and Necitumumab in-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors.
Nathaniel J Myall, Jennifer G Whisenant, Joel W Neal, Wade T Iams, Karen L Reckamp
JTO Clinical and Research Reports. 2025-02-01

Journal Articles

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
David S Shames, Leora Horn, Fairooz Kabbinavar, The New England Journal of Medicine

Lectures

Sequencing theTyrosine Kinase Inhibitors
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Real-world treatment patterns and survival of BRAF V600-mutated metastatic non-small cell lung cancer patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

How I Decided to Hold Out for the Best Lung Cancer TreatmentDecember 9th, 2022
Black, Low-Income Patients with Cancer at Highest Risk for Severe COVID-19 ComplicationsAugust 2nd, 2021
Kidney Damage from COVID-19 Linked to Higher Risk of in-Hospital DeathSeptember 22nd, 2020
Join now to see all